News List

Merck to acquire Rigontec to escalate immuno-oncology business


Merck, through a subsidiary, will make an upfront cash payment of €115 million to purchase Rigontec

By Team ABLE

Merck recently announced that it will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity.

Rigontec’s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.
Under the terms of the agreement, Merck, through a subsidiary, will make an upfront cash payment of €115 million to Rigontec’s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, Merck may make additional contingent payments of up to €349 million. The transaction is subject to certain closing conditions.

Rigontec was founded in 2014 as a spin-out of the University Bonn, Germany, and has to date raised close to €30 million from experienced life science investors including Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gru?nderfonds, MP Healthcare Venture Management, NRW.BANK, Sunstone Capital and Wellington Partners Life Sciences.